Pharma Pioneer

Unseen Challenges: The Quest for LGBTQIA+ Inclusivity in Patient Data

22 May 2024
3 min read

The SCOPE 2024 conference, inaugurated by Fareed Melhem of Medidata Solutions, emphasized the significance of integrating patient care with clinical research. The event underscored the pivotal role of patients in the drug development process, with a focus on the patient journey as essential for accurate data collection and the advancement of AI in pharmaceuticals.

Katherine Taylor of Merck & Co., who led a panel on integrating research into the care continuum, echoed the theme, highlighting opportunities to standardize patient participation across clinical research and care. The conference also addressed the inclusion of sexual and gender minority (SGM) patients in clinical trials, with the SGM Alliance facilitating discussions involving representatives from major pharmaceutical companies.

The first panel, "Inclusivity for the LGBTQIA+ Community: Count Me In," discussed the challenges faced by LGBTQIA+ patients, including biases in clinical trial protocols and healthcare provider attitudes. Personal narratives from participants underscored these issues, with anecdotes of misgendering and the need for patients to educate their healthcare providers.

Solomon Yakubov from GSK highlighted the difficulty of finding healthcare providers sensitive to the needs of sexual and gender minorities, even in urban areas. Garo Kiledjian, CEO of SGM Alliance, linked such experiences to a broader mistrust of healthcare and pharmaceuticals among these communities. Kiledjian also noted a growing industry dialogue on LGBTQIA+ inclusion, spurred by a previous conference roundtable.

Statistics from the National Institute on Minority Health and Disparities (NIMHD) show an increasing trend of LGBTQIA+ identification across generations. The FDA is actively requesting sexual orientation and gender identity (SOGI) data, signaling potential future requirements.

The SGM Alliance has partnered with numerous pharmaceutical companies, CROs, and technology providers, as well as government entities, to foster inclusion. The second panel, "Overcoming Access Barriers to Healthcare for the LGBTQIA+ Community: Bridging Gaps, Driving Change," moderated by Jessica Brescher, discussed strategies for increasing diversity in clinical trials, emphasizing the importance of detailed data collection and culturally sensitive practices.

Denise Johnson Sura from Eli Lilly shared her personal journey towards becoming more inclusive, focusing on language use and openness to learning. Sandra Amaro from Pfizer discussed the company's sponsorship of the Human Rights Campaign and the Healthcare Equity Index (HEI), a tool for evaluating healthcare facilities' LGBTQIA+ inclusivity.

Michel Reid from GSK emphasized the importance of communication and education for trial sites and healthcare providers, acknowledging the industry's ongoing learning process regarding data collection. Shir Netanel from Johnson & Johnson described the company's efforts to create inclusive trials, including a gender-neutral prostate cancer study that collects SOGI data.

As the pharmaceutical industry increasingly relies on AI, the importance of inclusive data collection grows, especially with the rising number of LGBTQIA+ individuals. Kiledjian advised companies to prepare for future requirements by actively including LGBTQIA+ populations in their protocols.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

PPTI Launches Phase I Trial for Zolmitriptan Microporation System in Migraine Treatment
Pharma Pioneer
2 min read
PPTI Launches Phase I Trial for Zolmitriptan Microporation System in Migraine Treatment
22 May 2024
San Diego-based PassPort Technologies, Inc. (PPTI) has launched a Phase 1 clinical trial in the United States for the Zolmitriptan PassPort® system, which employs a unique transdermal microporation system.
Read →
Expert Systems Marks Milestone: Lomonitinib Phase 1 Trials Completed in 3 Years
Pharma Pioneer
2 min read
Expert Systems Marks Milestone: Lomonitinib Phase 1 Trials Completed in 3 Years
22 May 2024
AI-driven drug discovery firm Expert Systems has reached a key milestone in collaboration with Eilean Therapeutics, having completed a Phase 1 clinical trial for lomonitinib, a targeted pan-FLT3/IRAK4 inhibitor.
Read →
Biodexa Reports Favorable Phase I DMG Trial Outcomes and R&D Progress
Pharma Pioneer
2 min read
Biodexa Reports Favorable Phase I DMG Trial Outcomes and R&D Progress
22 May 2024
Biodexa Pharmaceuticals PLC has reported encouraging preliminary results from a Phase I clinical trial for MTX110.
Read →
Frontier Medicines Secures $80M for KRAS Inhibitor Development, Challenges Amgen and BMS
Pharma Pioneer
2 min read
Frontier Medicines Secures $80M for KRAS Inhibitor Development, Challenges Amgen and BMS
22 May 2024
Frontier Medicines recently closed an $80 million Series C funding round, with plans to advance its novel KRAS blocker, FMC-376.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.